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The potential of human fetal bone cells for successful bone regeneration has been shown in vivo. In particular, 
it has been demonstrated that the seeding of these cells in porous poly-(L-lactic acid)/b-tricalcium phosphate 
scaffolds improved the bone formation compared to cell-free scaffolds in skulls of rats. However, even if the 
outcome is an improvement of bone formation, a thorough analysis concerning any immune responses, due to 
the implantation of a xenograft tissue, is not known. As the immune response and skeletal system relationship 
may contribute to either the success or failure of an implant, we were interested in evaluating the presence of 
any immune cells and specific reactions of human fetal cells (also called human bone progenitor cells) once 
implanted in femoral condyles of rats. For this purpose, (1) cell-free scaffolds, (2) human bone progenitor 
cells, or (3) osteogenic human bone progenitor cells within scaffolds were implanted over 3, 7, 14 days, and 
12 weeks. The key finding is that human bone progenitor cells and osteogenic human bone progenitor cells 
do not trigger any particular specific immune reactions in immunocompetent rats but are noted to delay some 
bone formation.
Key words: Bone tissue engineering (BTE); Scaffold; Cell therapy; Human bone progenitor cells (hBPCs); 
Immune response
INTRODUCTION
The high demand of bone tissue engineering scaffolds 
due to bone trauma, nonunions, or resection of tumors cre-
ates a great challenge in the field of bone regeneration1–3. 
Problems related to the use of auto- and allografts, such 
as limited supply, donor site morbidity, scarring, surgical 
risk, risk of infections, cost issues, and logistical chal-
lenges in creating bone banks4–7, have led to a growing 
interest in the field of bone tissue engineering (BTE) in 
the last three decades6. Therefore, the current aim of BTE, 
which matches the needs of the orthopedic medicine, is to 
obtain bone healing in the shortest time frame, with the 
best possible functional recovery associated with the least 
complications8. To achieve this goal, different approaches 
have been used, in which synthetic bone substitutes that 
have similar mechanical properties of bone in addition to 
allowing a sufficient vascularization are combined with 
either osteogenic engineered cells, morphogenic signals, 
or mechanical stimulations6,9–12.
Several approaches combining biomaterials with bone 
marrow preparations13,14, bone marrow-derived mesenchy-
mal stem cells (BM-MSCs)15,16, or osteoblasts6 were 
described to be promising for BTE. Furthermore, the 
potential of human fetal cells for a successful engineered 
regeneration of adult skeletal tissue has been shown in 
vitro and in vivo17,18. In these in vitro studies, it has been 
shown that human fetal cells, also called human bone 
progenitor cells (hBPCs), could be of great interest for 
bone research due to their rapid growth rate, advanced 
osteogenesis development, and ability to differentiate into 
mature osteoblasts. For this reason they are also referred 
to as osteogenic human bone progenitor cells (hOBPCs). 
In a later in vivo study, Montjovent et al.19 evaluated 
the effect of hBPCs in combination with porous poly- 
(L-lactic acid)/b-tricalcium phosphate (PLA/b-TCP) scaf-
folds. The cell-seeded scaffolds were implanted in skulls 
of rats, and a histological qualitative evaluation of bone 
repair at 12 days and at 6 and 12 months after implantation 
880 HAUSHERR ET AL.
was performed. The ossification along the dura and the 
porous ossification in scaffolds were analyzed, and it was 
found that the cell-seeded scaffolds improved the bone 
formation compared to cell-free scaffolds in this model.
Even though the final outcome was an improvement 
of bone formation, a thorough analysis concerning asso-
ciated immune responses with the implantation of a 
xenograft tissue is necessary. This kind of information is 
especially relevant to the envisioned clinical application 
of transplanting hBPCs into different patients, which will 
then represent an allograft. As the immune response and 
skeletal system relationship may contribute to either the 
success or failure of an implant20, we therefore investi-
gated what kind of immune response would be potentially 
triggered in an early stage of implantation of scaffolds 
seeded with hBPCs or without any cells as a control. 
Furthermore, hOBPC-seeded scaffolds were studied as 
well to get more information on the behavior of the dif-
ferentiated and mineralized state of hBPCs. Because these 
later cells may mature in vivo and become hOBPCs, a 
different immunological reaction could be triggered by 
the host. As little information is yet available concerning 
the difference in behavior between hBPCs and hOBPCs 
in vivo, we wanted to evaluate whether these different 
cell lineages have an influence on host immunity after 
they are first transplanted and on the long term. For this 
purpose, each scaffold group was implanted in both fem-
oral condyles of female Wistar rats, and a tissue analysis 
was performed after 3, 7, and 14 days as well as after 
12 weeks of implantation. In addition to the evaluation of 
immune reaction, the localization and eventual migration 
of the cells were of interest.
MATERIALS AND METHODS
Cell Culture
The hBPCs used in this study were obtained from a 
registered biobank (CHUV Lausanne, Switzerland), and 
cell bank development was approved by the local ethics 
committee (Protocols 51/10). The bone cells were har-
vested from a tissue donation under the registered 
Transplantation Program (fetal bone tissue of 15 weeks 
gestational age following a voluntary interruption of preg-
nancy) and treated as described elsewhere19. Briefly, hBPC 
cultures were established by rinsing the tissue first with 
phosphate-buffered saline (PBS; Thermo Fisher Scientific, 
Waltham, MA, USA) containing penicillin–streptomycin 
(Thermo Fisher, for washing only). Afterward, bone 
samples were mechanically dissociated with a scalpel 
blade and transferred to 10-cm culture-grade plates where 
cell outgrowth was seen within 2 to 5 days under normal 
culture conditions: Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, Carlsbad, CA, USA), 10% fetal 
calf serum (FCS; Sigma-Aldrich, St. Louis, MO, USA), 
and 2 mM L-glutamine (Invitrogen). For cell expansion, 
the cells were cultured in T75 flasks (TPP® tissue cul-
ture flask; Sigma-Aldrich) in a standard culture medium 
composed of DMEM, supplemented with 10% (v/v) fetal 
bovine serum (FBS; Thermo Fisher Scientific) and 1% 
(v/v) L-glutamine (200 mM). They were maintained in 
culture at 37°C in 5% CO2 atmosphere with culture media 
changed twice weekly and were passaged when they 
reached 80% confluency. When the hOBPCs were used 
for in vivo experiments, the following osteogenic differ-
entiation medium was prepared: a-minimum essential 
medium Eagle (MEM; Gibco, Thermo Fisher Scientific), 
10% (v/v) FBS, 1% (v/v) L-glutamine (200 mM), 1% 
(v/v) vitamin C (5 mg/ml; Sigma-Aldrich), 1% (w/v) 
b-glycerophosphate (500 mM; Sigma-Aldrich), and 1% 
(w/v) dexamethasone (1 mM; Sigma-Aldrich). The cells 
were first plated in a standard culture medium and then 
exposed to the osteogenic differentiation medium at the 
third day of culture. The medium was renewed three 
times a week over 2 weeks.
Scaffold Fabrication
The scaffolds used in this work were developed in col-
laboration with the Laboratory of Polymer and Composite 
Technology (LTC, EPFL, Lausanne, Switzerland). The 
processing and properties analysis of the scaffolds were 
carried out as described elsewhere21. In short, the scaf-
folds were made of polylactic acid (PLA; Boehringher 
Ingelheim, Ingelheim am Rhein, Germany) and b-TCP 
ceramic powder (Sigma-Aldrich), which were mixed 
(5%, w/w) and melt extruded using a microcompounder 
(Xplore, Geleen, Netherlands). Afterward, the melt- 
extruded product was foamed with supercritical CO2 in a 
custom-made high-pressure chamber. Once the CO2 was 
dissolved in PLA, foaming was achieved by sudden gas 
release, which induces bubble nucleation and formation. 
The rising porous structure was then fixed by simulta-
neously cooling and depressurizing the high-pressure 
chamber19. The final volume of synthetic composite 
PLA/5% b-TCP used for the in vivo study was machined 
into cylinders of 3-mm height and 3-mm diameter.
Scaffold Preparation and Seeding
The PLA/5% b-TCP scaffolds were sterilized by eth-
ylene oxide at the CHUV (Lausanne, Switzerland). Prior 
to the cell seeding, the scaffolds were wet and sonicated 
(Ultrasonik; Ismatec SA, Werheim, Germany) for 20 min 
in order to avoid the entrapment of micro-air bubbles in 
the scaffold. The cells were seeded at passage 4 at a con-
centration of 0.5 ´  106 cells/scaffold in PLA/5% b-TCP 
scaffolds using a pressure-driven technique. Once seeded, 
the scaffolds were placed on a rotating platform, allow-
ing a homogeneous cell distribution inside the scaffold. 
For the in vivo study, we distinguished between three 
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different types of scaffolds: cell-free (CF), seeded with 
hBPC (CS), and seeded with hOBPC (OCS) scaffolds. 
In the case of CF scaffolds, the scaffolds were wet with 
0.9% NaCl solution (B. Braun, Melsungen, Germany) for 
the sonication and then left in 200 µl of 0.9% NaCl solu-
tion for 72 h in the incubator before implantation. For 
the CS scaffold, the scaffolds were wet with standard cul-
ture medium and were seeded with hBPCs 3 days before 
implantation, whereas OCS scaffolds were seeded with 
hBPCs 2 weeks before implantation for in vivo experi-
mentation. The medium of OCS scaffolds was changed 
three times a week with osteogenic differentiation medium 
to obtain hOBPC-seeded scaffolds. Just before implanta-
tion, every scaffold was washed three times with sterile 
0.9% NaCl solution.
Study Design
The in vivo study included three experimental groups 
defined by the implanted PLA/5% b-TCP scaffold type 
(CF, CS, and OCS). Each type of scaffold was implanted 
in a predrilled hole in both femoral condyles of rats. In 
each experimental group, 15 rats were operated. Three to 
four of the rats were euthanized either at 3, 7, and 14 days 
or at 12 weeks after implantation in order to detect any 
immune reaction possibly due to the use of hBPCs and 
hOBPCs. Blood samples were collected before the surgi-
cal intervention and before euthanasia to make a white 
blood cell count analysis at time points 3, 7, and 14 days 
of implantation.
Surgical Procedure
All animal procedures were performed with the 
approval of the local animal care and use committee 
(License No. 2631.0; EXPANIM, SCAV, Epalinges, 
Switzerland). Female Wistar rats (280–300 g) were pur-
chased from Janvier Labs (Saint-Berthevin, France). For 
implanting scaffolds in femoral condyles of rats, the pro-
tocol was slightly adapted from Roshan-Ghias et al.22,23. 
The rats were anesthetized with isoflurane gas (induc-
tion: 5% at 2.0 L/min, during surgery: 2.5% at 0.8 L/min; 
Piramal Enterprise Ltd., Bombay, India). After anesthesia 
induction, blood was taken from the rat’s tail. The ani-
mal’s legs were shaved, and buprenorphine (0.03 mg/
kg/day; Temgesic®; Reckitt Benckiser AG, Wallisellen, 
Switzerland) was injected subcutaneously as analgesia. 
The animal was then situated on a custom-made table to 
fix and to stabilize the leg. After 1- to 2-cm skin inci-
sion on the lateral side of the distal femoral end and 
muscle dissection24, a hole with a diameter of 3 mm and 
height of 3 mm was drilled in the condyle underneath the 
growth plate using a motorized dentist’s drill (DEC 100; 
Nobel Biocare, Karlskoga, Sweden). Before and after the 
drilling, the site of implantation was cooled and rinsed 
with 0.9% NaCl. Afterward, either a CF, CS, or OCS 
PLA/5% b-TCP scaffold was implanted by press fitting 
it inside the drilled hole. The muscles and skin were then 
closed with synthetic absorbable sterile surgical sutures 
[coated VICRYL® (polyglactin 910); 5-0; Ethicon Inc., 
Somerville, NJ, USA] with interrupted subcutaneous 
stitches [coated VICRYL® (polygalctin 910); 5-0]. The 
animal was then prepared to make the same surgical 
intervention on the contralateral femur. Buprenorphine 
was injected subcutaneously every 8 h for the first 72 h 
after surgery for pain relief completed by the addition 
of paracetamol (Dafalgan; 500 mg effervescent tablet; 
UPSA Bristol-Myers Squibb SA, Baar, Switzerland) to 
the drinking water of the rats for 1 week. Intracardiac 
blood samples were collected before the euthanasia of 
rats at 3, 7, and 14 days after scaffold implantation. All 
rats were euthanized with an intracardiac pentobarbital 
(<200 mg/kg; Esconarkon; Streuli Pharma SA, Uznach, 
Switzerland) injection.
Blood Smear Staining and Leukocyte Count
After rat blood collection, a drop of blood was smeared 
on a glass slide (Polysciences Inc., Warrington, PA, USA). 
The samples were then stained with Hemacolor® Rapid 
staining (Merck Millipore Corporation, Billerica, MA, 
USA) according to the manufacturer’s instructions. This 
staining is based on the Pappenheim staining technique, 
which enables the differential counts of white blood cells 
including lymphocytes, monocytes, nonsegmented neutro-
phils, juvenile neutrophils, segmented neutrophils, eosino-
phils, and basophils based on their morphology. Two 
separate investigators counted 100 cells for each sample, 
and the results were averaged for the statistical analysis.
Histology
After blood sample collection, the animals were directly 
euthanized, and femur distal parts were dissected and 
fixed in 4% paraformaldehyde (PFA; Sigma-Aldrich) 
solution for approximately 1 day. The samples were dehy-
drated by immersing them in a series of ethanol (EtOH; 
VWR International, Dietikon, Switzerland) solutions with 
ascending concentration (70%, 80%, 90%, 96%, and 
100%) as described elsewhere24. Each immersion lasted 
for 24 h. The samples were then cleared 1 ´  24 h in tolu-
ene (VWR International) and then again in a refreshed 
toluene solution for 1 ´  48 h. Afterward, two thirds of 
the femur samples were embedded by infiltration with 
methylmethacrylate (MMA; 100 ml; Sigma-Aldrich) and 
0.5% bis(tert-butylcyclohexyl)peroxydicarbonate (Perka-
dox 16; Dr Grogg Chemie AG, Deisswil, Switzerland) 
at 4°C for 5 days. For polymerization, 100 ml of MMA, 
20–25 ml of dibutyl phthalate (DBP; Sigma-Aldrich), 
and 1% of Perkadox 16 (Dr Grogg Chemie AG) were 
prepared, and the samples were polymerized at room 
temperature (RT) over 3 weeks. The left one third of the 
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samples were embedded in Technovit 9100 (Heraeus 
Kulzer GmbH, Hanau, Germany) according to the man-
ufacturer’s instructions. The Technovit 9100 has a poly-
merization temperature between −4°C and 0°C, which 
allows the preservation of DNA and RNA. After poly-
merization, MMA- and Technovit 9100-embedded samples 
(referred to as resin blocks) were cut with a diamond-
coated inner diameter saw (Leica SP 1600; Leica Micro- 
systems, Wetzlar, Germany) into slices of around 180-µm 
thickness (referred to as thick slice). Four to five of these 
MMA preparations were cut and attached to custom- 
made opaque o-methyl methacrylate (OMMA) microscope 
slides (Semadeni AG, Ostermundigen, Switzerland) with 
acrylic glue (Loctite 401; Henkel, Düsseldorf, Germany). 
They were then ground to around 80- to 100-µm thick-
nesses with a grinding machine (Pedemax-2; Struers, 
Willich, Germany) before staining. The rest of the Technovit 
9100 resin blocks were cut with a microtome (HM325; 
Microm International GmbH, Walldorf, Germany) into 
slices of around 10 µm (referred to as thin slide). They 
were attached on silane glass slides (Polysciences) with 
90% EtOH. Finally, the slides were clamped at 37°C over 
48 h and released for at least 2 h at RT before staining.
The surface of the thick slides was etched with 1% 
formic acid (AppliChem, Darmstadt, Germany) before 
being stained with 0.1% toluidine blue (VWR Inter-
national). For the thin slides, the resin was deplastified 
with a series of different bathes. First, the slides were 
immersed three times for 20 min in toluene (VWR Inter-
national), followed by hydration in a series of EtOH with 
a descending concentration (100%, 90%, 80%, and 70%); 
slides were immersed for 10 min each. The slides were 
finally put in deionized water before human-specific Alu 
in situ hybridization (Alu-ISH) for the detection of hBPCs. 
Positive controls, provided by the histology facility, were 
simultaneously run with our samples. The positive controls 
were human tissue (heart, skin, or demineralized bone) 
embedded in paraffin. The Alu-ISH was performed using a 
fluorescein isothiocyanate (FITC)-labeled human-specific 
Alu probe (Roche Diagnostics, Rotkreuz, Switzerland). 
The Alu-ISH on rat femur resin sections was done using 
the fully automated instrument Ventana Discovery xT 
(Roche Diagnostics). All steps, except the deplastification 
described previously, were performed on the machine 
with Ventana solutions (Roche Diagnostics), as described 
elsewhere25,26. Briefly, deplastified and rehydrated resin 
sections were pretreated with the RiboMap kit (Roche 
Diagnostics) and with protease 1 (Roche Diagnostics) for 
8 min at 37°C. The human-specific Alu probe was hybrid-
ized for 1 h at 47°C. Sections were then washed three 
times with Ribowash [2´ saline sodium citrate (SSC) 
buffer with 0.1% sodium dodecyl sulfate (SDS); Roche 
Diagnostics] for 8 min at 45°C. After incubation with 
an anti-FITC biotin (1:300; Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA), chromogenic rev-
elation was performed with the BlueMap kit for 2 h. 
Counterstain using Nuclear Fast Red (Carl Roth GmbH 
& Co. KG, Karlsruhe, Germany) was performed on a 
Tissue-Tek® Prisma® automate (Sakura Finetek, Alphen aan 
den Rijn, Netherlands) for 5 min. Slides were mounted with 
a xylene-based glue (Sakura Finetek).
Images were taken with an upright light microscope 
with different magnifications (DM 5500; Leica Micro-
systems). Based on the stained sections, a qualitative 
evaluation was performed, where cellular events were 
interpreted. The osteoblast activation, shape, and the pres-
ence of inflammatory cells (neutrophils, macrophages, 
lymphocytes, plasma cells, multinuclear giant cells, and 
fibrous capsule) were observed and commented. The per-
centage of fibrous tissues and maturity of the bone were 
evaluated inside the scaffold.
Statistical Analysis
The results obtained for the leukocyte count were 
analyzed using a t-test. At each time point, it was tested 
whether there was a significant difference between the 
different scaffolds (n = 3–4). A value of p < 0.05 or p < 0.01 
was considered as significant. All statistical analyses were 
done in R (R Development code Team 2010, Auckland, 
New Zealand).
RESULTS
Cell Visualization and Localization
For the localization of hBPCs inside and around the 
scaffold with an eventual observation of a migration 
pattern outside the scaffold over time, we used human-
specific Alu elements with in situ hybridization of thin 
deplastified resin slides. For this application, we chose 
a specific resin (Technovit 9100) with a polymerization 
temperature around 0°C in order to avoid the DNA and 
RNA denaturization due to temperature. The obtained 
results are shown in Figure 1. Two samples out of 20 
did polymerize correctly, where one of them was our 
first test sample (CS condition, after 4 days of implanta-
tion) and the second one was an OCS scaffold at 14 days 
postimplantation.
On both stained samples, hBPCs and hOBPCs were 
detected inside the scaffold. In the case of the CS scaf-
fold, which was implanted for 4 days, the cells were vis-
ible in different regions inside and at the border of the 
scaffold (black arrow heads). They were localized inside 
the pores at their surface. On the left top image, we can 
observe a cluster of cells. On the images from the OCS 
scaffold, implanted for 14 days, few cells were detected, 
localized in pores near the border. In this case, the cells 
seem not to adhere at the surface of the pores but are seen 
inside the pores, surrounded by the extracellular matrix 
and other cells.
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Hematology
The results of the differential leukocyte count after 3, 
7, and 14 days of implantation are shown in Figure 2. 
The leukocyte count of days 3, 7, and 14 were all nor-
malized to the leukocyte count of day 0. After 3 days of 
implantation, no significant differences were observed in 
the percentage of different white blood cells in between 
the scaffold conditions as presented (Fig. 2a).
Results at day 7 are presented in Figure 2b. A statisti-
cally significant increase in lymphocytes can be observed 
for the OCS scaffolds compared to the CF and CS scaf-
folds, whereas there is a decrease in monocytes and 
nonsegmented and juvenile neutrophils for the OCS scaf-
folds. The segmented neutrophils, however, augmented 
for the CF scaffolds compared to the CS and OCS scaf-
folds. The number of eosinophils and basophils stayed in 
all three scaffold conditions quite similarly. After 14 days 
of implantation for monocyte levels, one can observe a 
statistically significant increase between the CF and OCS 
scaffolds and between the CF and CS scaffolds (Fig. 2c). 
In general, over time, the level of lymphocytes increased 
for all three scaffold conditions over the 14 days, whereas 
the monocyte, juvenile neutrophil, and nonsegmented 
and segmented neutrophil levels tended to decrease.
Histology
The histology images of implanted OCS, CS, and 
CF scaffolds after 3, 7, and 14 days and after 12 weeks 
are shown in Figures 3–5, respectively. For qualitative 
assessment, the results are shown in Tables S1 and S2 
(supplementary material available at http://infoscience.
epfl.ch/record/221050). In the case of the OCS and CS 
scaffolds, 25%–75% and 25%–30% of fibrous tissues were 
present inside the scaffold over the first 14 days, respec-
tively (Table S1). In both conditions, it partially formed 
at the top and around the scaffold without encapsulating 
the scaffold. In the case of the CF scaffolds, 10%–15% of 
fibrous tissue was observed inside the scaffold coming 
from the top of the scaffold (Table S1). After 12 weeks 
of implantation, 5%–15%, 5%–10%, and 10%–75% of 
fibrous tissues were observed in the CF, CS, and OCS 
scaffolds, respectively (Table S1). In the early stage of 
implantation, CF scaffolds were in direct contact with the 
surrounding bone. In all three conditions, osteoblast acti-
vation toward the scaffolds as well as newly formed bone 
at the bottom of the scaffold were observed over the first 
14 days of implantation. Many red blood cells are visible 
for all three scaffold conditions, mainly at days 3 and 7 
(Figs. 3–5). The neutrophils, macrophages, lymphocytes, 
plasma cells, and multinuclear giant cells were qualita-
tively rarely observed in the three scaffold conditions 
(Table S2). A slightly higher amount of those cells were 
observed in the case of the CF scaffolds compared to the 
CS and OCS scaffolds. For all scaffold conditions and 
time points, the amount of observed immune cells was 
in the normal range (Table S2). Inside the OCS and the 
Figure 1. Alu-ISH with a counter Nuclear Fast Red stain on sections of CS scaffolds after 4 days and on sections of OCS scaffolds 
after 14 days of implantation. The black arrowheads indicate the hBPCs and hOBPCs (in blue) inside the scaffolds. TB, trabecular 
bone; CB, cortical bone; SF, scaffold; Alu-ISH, Alu in situ hybridization; CS, scaffold seeded with hBPCs; OCS, scaffold seeded with 
hOBPCs; hBPCs, human bone progenitor cells; hOBPCs, osteogenic human bone progenitor cells.
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FACING PAGE
Figure 2. Normalized leukocyte count in blood taken after (a) 3 days, (b) 7 days, and (c) 14 days of CF, CS, and OCS scaffold 
implantation in femoral condyles of rats, respectively. Blood smears (with n = 3–4) were analyzed using the Pappenheim method. 
The lymphocytes, monocytes, nonsegmented, juvenile, and segmented neutrophils, eosinophils, and basophils after 3, 7, and 14 days 
of implantation were normalized to the one just before implantation (day 0). *p < 0.05 and **p < 0.01. CF, cell-free scaffold; CS, scaf-
fold seeded with hBPCs; OCS, scaffold seeded with hOBPCs; hBPCs, human bone progenitor cells; hOBPCs, osteogenic human bone 
progenitor  cells.
Figure 3. Toluidine blue-stained sections of OCS scaffolds after 3, 7, and 14 days and after 12 weeks of implantation. TB, trabecular 
bone; CB, cortical bone; BM, bone marrow; SF, scaffold; rBC, red blood cells; FT, fibrous tissue; ECM, extracellular matrix; iB, 
immature bone; mB, mature bone modeling; OCS, scaffold seeded with hOBPCs; hOBPCs, osteogenic human bone progenitor cells.
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CS scaffolds, one can see the extracellular matrix of the 
implanted cells, which is totally absent in the implanted 
CF scaffolds after 3, 7, and 14 days of implantation 
(Figs. 3 and 4). Immature bone started to grow inside 
the scaffold after 7 days and started to mineralize after 
14 days of implantation for the implanted OCS, CS, and 
CF scaffolds. In the later case, the mineralization pro-
cess was more pronounced and evolved than in the two 
other conditions. After 12 weeks of implantation, totally 
mature bone and active BM were observed in the CF 
scaffolds, whereas the bone maturity and BM activity in 
the CS and OCS scaffolds were less advanced and in a 
more immature state.
DISCUSSION
The use of hBPCs for BTE has been demonstrated to 
be promising17,19. As a xenograft tissue engineering scaf-
fold is implanted in immunocompetent rats, the aim of 
Figure 4. Toluidine blue-stained sections of CS scaffolds after 3, 7, and 14 days and after 12 weeks of implantation. TB, trabecular 
bone; CB, cortical bone; BM, bone marrow; SF, scaffold; rBC, red blood cells; FT, fibrous tissue; ECM, extracellular matrix; iB, 
immature bone; mB, mature bone modeling; CS, scaffold seeded with hBPCs; hBPCs, human bone progenitor cells.
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this study was to evaluate in vivo the potential type of 
immune reaction triggered by hBPCs and hOBPCs at 
an early stage of implantation and on the long term. We 
therefore implanted the scaffolds in femoral condyles of 
rats and analyzed them after 3, 7, and 14 days and after 
12 weeks of implantation. Key findings of this study were 
(1) the enhancement of fibrous tissue formation in the 
OCS and CS scaffolds compared to the CF scaffolds in 
the early stage of implantation, while all three types of 
scaffolds had a comparable amount of immune cells on 
site; (2) the lack of fibrous capsule around the CS and 
OCS scaffolds after 12 weeks of implantation; and (3) the 
remodeling of healthy bone tissue inside the CS and OCS 
scaffolds with a delay compared to CF on the long term.
We first localized and visualized in vivo hBPCs for 
the first time by using an Alu-ISH on resin slides after 
Figure 5. Toluidine blue-stained sections of CF scaffolds after 3, 7, and 14 days and after 12 weeks of implantation. TB, trabecular 
bone; CB, cortical bone; BM, bone marrow; SF, scaffold; rBC, red blood cells; FT, fibrous tissue; ECM, extracellular matrix; iB, 
immature bone; mB, mature bone modeling; CF, cell-free scaffold.
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having characterized their ability to differentiate into 
osteoblasts when cultured in vitro (Supplementary mate-
rials, Figs. S1–S3). On these slides, we observed that 
both hBPCs and hOBPCs were still on site after 4 and 
14 days of implantation in vivo. Because of techni-
cal problems, a limited number of samples could be 
processed. Therefore, we could only draw qualitative 
information on the presence of hBPCs and hOBPCs in 
the implanted sites. Should a better scaffold process-
ing for immunohistochemistry in PLA/5% b-TCP scaf-
folds be possible, it would be interesting to (1) evaluate 
the difference between hBPCs and hOBPCs in terms 
of localization and migration kinetics and (2) evaluate 
in a more precise way the immune reaction by target-
ing specific cytokines, growth factors, and extracellular 
matrix components.
We then performed differential leukocyte counts and 
histological evaluations. We showed that the implantation 
of hBPCs and hOBPCs in immunocompetent rats did not 
trigger any specific immune response, even if they initi-
ated a temporal formation of fibrous tissue at an early 
stage of implantation.
For the hematological analysis, significant differences 
were observed between the different scaffold conditions 
after 7 and 14 days of implantation. The increase in per-
centage of lymphocytes was statistically significant in 
the OCS scaffolds compared to the CS and CF scaffolds, 
whereas the percentage of monocytes and nonsegmented 
and juvenile neutrophils showed the inverse behavior 
after 7 days of implantation. At the same time point, 
the segmented neutrophils showed a higher percentage 
for the CF scaffolds than for the CS and OCS scaffolds. 
After 14 days of implantation, the monocyte percentage 
was significantly lower for the CF scaffolds than for the 
two others types of scaffolds. Comparing the values of 
the different types of white blood cells with other pub-
lications27–29, we found that they were within the normal 
range for Wistar and Sprague–Dawley rats, except for 
the monocyte values. As the percentage of monocytes 
had values in the same range at day 0 than after 3, 7, and 
14 days, we considered that there was no acute hemato-
logical effect due to the implantation of CF, CS, and OCS 
scaffolds.
The histological evaluation clearly showed that the 
presence of the immune cells, such as neutrophils, mac-
rophages, lymphocytes, plasma cells, and multinuclear 
giant cells, was rarely observed in all three conditions 
from 3 to 14 days of implantation, while fibrous tissue 
was seen with the CS and OCS scaffolds. We observed, 
as well, a higher fibrous tissue formation in OCS scaf-
folds compared to CS scaffolds. As the immune response 
and the skeletal system work closely together, the 
immune cells play a pivotal role in determining the in 
vivo fate of the implanted material by contributing either 
to its success by facilitating new bone formation or to 
its failure with the creation of an inflammatory fibrous 
tissue capsule20,30. The results obtained after 12 weeks 
of implantation indicate that the host’s body overcame 
the fibrous tissue formation instead of encapsulating 
the xenograft BTE scaffold. The histological evaluation 
indicated that the time needed to remodel the fibrous tis-
sue in bone tissue inside the CS and OCS scaffolds was 
expressed by less mature bone formation and BM activ-
ity after 12 weeks of implantation compared to the CF 
scaffolds. However, the fibrous tissue formation in the 
CS and OCS conditions at an early stage of implantation 
could be favored by another cellular mechanism or cel-
lular secretion, which arose certainly from the implanted 
hBPCs themselves. As cell fate is a temporal, spatial, 
and mechanical interplay between cells, cytokines, and 
growth factors6, it is merely impossible to describe the 
interaction of the implanted hBPCs and the surround-
ing rat tissue. A possible cue could be given in a study 
published by Safadi et al.31. They demonstrated that 
connective tissue growth factor (CTGF) was expressed 
in normal bone during active growth or modeling and 
that its expression increased during the matrix miner-
alization and proliferation of primary osteoblasts from 
neonatal rats. This expression increases during mineral-
ization, and proliferation of primary osteoblast could be 
a plausible explanation for the observed higher increase 
in fibrous tissue in OCS scaffolds compared to CS scaf-
folds. Other publications described that this growth 
factor was important in osteogenesis but played rather 
a more relevant role in fibrogenesis32,33. Therefore, the 
temporal effect of secreted CTGF could cause the pres-
ence of formed fibrous tissue from hBPCs and hOBPCs. 
In order to demonstrate this hypothesis, further in vitro 
and in vivo studies would be needed. In the case of in 
vitro studies, CTGF secretion of hBPCs and hOBPCs 
could be compared to those of rat BPCs (rBPCs) and 
endothelial cells, first observed and described to secrete 
CTGF34. Furthermore, additional in vivo experiments 
should give proof that the insertion of BPCs influences 
the formation of fibrous tissue, by analyzing the effect of 
implanted scaffolds seeded with either rBPCs or osteo-
genic rBPCs in rats. If in this last experiment a lower 
amount of bone density was observed using different 
types of cells originating from rat, it would confirm that 
the PLA/5% b-TCP scaffold used in this study is a sys-
tem having the required quality to be applied in clinics 
without cell therapy. If, on the other hand, this in vivo 
experiment would show a significant increase in bone 
density inside scaffolds seeded with rat-affiliated cells, a 
potential clinical application of hBPCs in humans could 
be reconsidered.
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